These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 18309035)
1. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Taskinen M; Karjalainen-Lindsberg ML; Leppä S Blood; 2008 May; 111(9):4664-7. PubMed ID: 18309035 [TBL] [Abstract][Full Text] [Related]
2. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969 [TBL] [Abstract][Full Text] [Related]
4. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945 [TBL] [Abstract][Full Text] [Related]
5. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Hiddemann W; Kneba M; Dreyling M; Schmitz N; Lengfelder E; Schmits R; Reiser M; Metzner B; Harder H; Hegewisch-Becker S; Fischer T; Kropff M; Reis HE; Freund M; Wörmann B; Fuchs R; Planker M; Schimke J; Eimermacher H; Trümper L; Aldaoud A; Parwaresch R; Unterhalt M Blood; 2005 Dec; 106(12):3725-32. PubMed ID: 16123223 [TBL] [Abstract][Full Text] [Related]
6. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Press OW; Unger JM; Rimsza LM; Friedberg JW; LeBlanc M; Czuczman MS; Kaminski M; Braziel RM; Spier C; Gopal AK; Maloney DG; Cheson BD; Dakhil SR; Miller TP; Fisher RI Clin Cancer Res; 2013 Dec; 19(23):6624-32. PubMed ID: 24130072 [TBL] [Abstract][Full Text] [Related]
7. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. Casulo C; Byrtek M; Dawson KL; Zhou X; Farber CM; Flowers CR; Hainsworth JD; Maurer MJ; Cerhan JR; Link BK; Zelenetz AD; Friedberg JW J Clin Oncol; 2015 Aug; 33(23):2516-22. PubMed ID: 26124482 [TBL] [Abstract][Full Text] [Related]
8. Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP. Taskinen M; Valo E; Karjalainen-Lindsberg ML; Hautaniemi S; Meri S; Leppä S Clin Cancer Res; 2010 May; 16(9):2615-23. PubMed ID: 20388848 [TBL] [Abstract][Full Text] [Related]
9. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era. Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321 [TBL] [Abstract][Full Text] [Related]
10. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. van Oers MH; Klasa R; Marcus RE; Wolf M; Kimby E; Gascoyne RD; Jack A; Van't Veer M; Vranovsky A; Holte H; van Glabbeke M; Teodorovic I; Rozewicz C; Hagenbeek A Blood; 2006 Nov; 108(10):3295-301. PubMed ID: 16873669 [TBL] [Abstract][Full Text] [Related]
11. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. Luminari S; Ferrari A; Manni M; Dondi A; Chiarenza A; Merli F; Rusconi C; Tarantino V; Tucci A; Vitolo U; Kovalchuk S; Angelucci E; Pulsoni A; Arcaini L; Angrilli F; Gaidano G; Stelitano C; Bertoldero G; Cascavilla N; Salvi F; Ferreri AJM; Vallisa D; Marcheselli L; Federico M J Clin Oncol; 2018 Mar; 36(7):689-696. PubMed ID: 29095677 [TBL] [Abstract][Full Text] [Related]
12. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era. Procházka V; Papajík T; Faber E; Raida L; Kapitáňová Z; Langová K; Prouzová Z; Jarošová M; Indrák K Leuk Lymphoma; 2014 Jul; 55(7):1584-90. PubMed ID: 24180329 [TBL] [Abstract][Full Text] [Related]
13. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554 [TBL] [Abstract][Full Text] [Related]
14. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Buske C; Hoster E; Dreyling M; Hasford J; Unterhalt M; Hiddemann W Blood; 2006 Sep; 108(5):1504-8. PubMed ID: 16690968 [TBL] [Abstract][Full Text] [Related]
15. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Harjunpää A; Taskinen M; Nykter M; Karjalainen-Lindsberg ML; Nyman H; Monni O; Hemmer S; Yli-Harja O; Hautaniemi S; Meri S; Leppä S Br J Haematol; 2006 Oct; 135(1):33-42. PubMed ID: 16925574 [TBL] [Abstract][Full Text] [Related]
16. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. Dupuis J; Berriolo-Riedinger A; Julian A; Brice P; Tychyj-Pinel C; Tilly H; Mounier N; Gallamini A; Feugier P; Soubeyran P; Colombat P; Laurent G; Berenger N; Casasnovas RO; Vera P; Paone G; Xerri L; Salles G; Haioun C; Meignan M J Clin Oncol; 2012 Dec; 30(35):4317-22. PubMed ID: 23109699 [TBL] [Abstract][Full Text] [Related]
17. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Overman MJ; Feng L; Pro B; McLaughlin P; Hess M; Samaniego F; Younes A; Romaguera JE; Hagemeister FB; Kwak L; Cabanillas F; Rodriguez MA; Fayad LE Ann Oncol; 2008 Mar; 19(3):553-9. PubMed ID: 18083690 [TBL] [Abstract][Full Text] [Related]